alexa Pharmaceutical Equivalence and Bioequivalence of Radiopharmaceuticals: Thinking the Possibility of Generic Radiopharmaceuticals and Preparing for New Technology as Nanotechnology Drugs | Open Access Journals
ISSN: 0975-0851
Journal of Bioequivalence & Bioavailability
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Pharmaceutical Equivalence and Bioequivalence of Radiopharmaceuticals: Thinking the Possibility of Generic Radiopharmaceuticals and Preparing for New Technology as Nanotechnology Drugs

Ralph Santos-Oliveira*

Brazilian Association of Radiopharmacy, Laboratory of Nanoradiopharmaceuticals, Rio de Janeiro, Brazil

*Corresponding Author:
Ralph Santos-Oliveira
Brazilian Association of Radiopharmacy
Laboratory of Nanoradiopharmaceuticals
Av. Manuel Caldeira de Alvarenga–UEZO–Campo Grande
Rio de Janeiro, Brazil
Tel: +552121733964
E-mail: [email protected]

Received Date: November 04, 2013; Accepted Date: January 23, 2014; Published Date: January 30, 2014

Citation: Santos-Oliveira R (2014) Pharmaceutical Equivalence and Bioequivalence of Radiopharmaceuticals: Thinking the Possibility of Generic Radiopharmaceuticals and Preparing for New Technology as Nanotechnology Drugs. J Bioequiv Availab 6: 023-023. doi: 10.4172/jbb.1000175

Copyright: © 2014 Santos-Oliveira R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Bioequivalence & Bioavailability

Letter

The use of radiopharmaceuticals has been growing exponentially throughout the world, achieving notable numbers. Recent data estimates that in 2015 the market of Nuclear Medicine and Radiopharmacy surpass the mark of 1.5 trillion dollars, with more than 100 million people making use of these drugs around the world. In this scenario, so overwhelming, is surprising that there has not begun studies of pharmaceutical equivalence and bioequivalence of such drugs, especially with animal model and for therapeutics uses.

Pharmaceutical equivalents is understood as drugs that have the same dosage form, route of administration and the same amount of the same active substance, that is, the same salt or ester of therapeutic molecule, or may contain excipients not identical, since well-established intended function. Equivalent pharmaceuticals, must comply with the same requirements of the Pharmacopoeia monograph, preferably with or other official compendia, rules or regulations adopted or, in their absence, with other standards of quality.

Bioequivalence, in order hand, is used to demonstrate pharmaceutical equivalence between products which have the same pharmaceutical form, containing the same qualitative and quantitative composition of principle(s) active(s), and have comparable bioavailability when studied under the same experimental design.

Obviously there must be considered the various existing laws around the world that deal with radiopharmaceuticals, however, this factor can not be individually responsible for the absence of such studies. The availability of generic radiopharmaceuticals should be viewed as a reality, whether by producers, either by the inspectors. The current situation of lack of such generics on the market, should not be a limiting factor for the future development of such reality. Meanwhile, the advance of new technologies, especially nanotechnology and hence nanoradiopharmaceuticals, become each day closer to becoming reality, and thus, both the concepts of pharmaceutical equivalence and bioavailability should already be updated so that they address this class of drugs, as well as radiopharmaceuticals and thus not be a legal.

In a pioneering and sustained by the poignant need to decrease costs related to nuclear medicine procedures, this letter proposes the initiation of studies in the direction of generic-radiopharmaceuticals and thus increase access and quality of procedures in radiopharmacy and nuclear medicine globally.

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11635
  • [From(publication date):
    January-2014 - Sep 22, 2017]
  • Breakdown by view type
  • HTML page views : 7861
  • PDF downloads :3774
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords